opyl glycinate hydrochloride,

2-fluoro-N-[(1R)-2-hydroxy-1-methylethyl]-4-(5-{(1R)-1-[4-(5-isopropyl-1,2,4-oxadiazol-3-yl)phenoxy]propyl}-1,2,4-oxadiazol-3-yl)benzamide, and

N-(cyclopropylmethyl)-2-fluoro-4-(5-{(1R)-1-[4-(5-isopropyl-1,2,4-oxadiazol-3-yl)phenoxy]propyl}-1,2,4-oxadiazol-3-yl)benzamide.

17. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 16, for use in treating and/or preventing type 1 diabetes, type 2 diabetes, a diabetes-associated disease, or obesity.

18. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 16, for use in protecting β cells or the pancreas.

~~17~~19. A pharmaceutical composition comprising, as an active ingredient, the compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 16.

~~18~~20. The pharmaceutical composition according to claim ~~17~~ 19, for use in treating and/or preventing type 1 diabetes, type 2 diabetes, a diabetes-associated disease, or obesity.

~~19~~21. The pharmaceutical composition according to claim ~~17~~ 19, for use in protecting β cells or the pancreas.

~~20~~22. Use of the compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 16, for the manufacture of a medicament for treating and/or preventing type 1 diabetes, type 2 diabetes, a diabetes-associated disease, or obesity.